medline.ch Onkologie Gynäkologische Tumoren

	Effectiveness of a Smartphone-Based Self-Management App (BeHealth app) for Women with Breast Cancer: A Randomized Controlled Trial. Iran J Public Health Kim HS, Kim HJ. PMID: 42428742 [PubMed - in process]
	Cost-effectiveness analysis of pyrotinib combined with trastuzumab and docetaxel as first-line treatment for HER2-positive metastatic breast cancer in China. Front Pharmacol Liang M, Liu S, Zhang X, Liu Q. PMID: 42428506 [PubMed - in process]
	Treatment of recurrent low grade serous ovarian cancer: MEK inhibition and the RAMP 201 trial. Gynecol Pelvic Med Ali M, Brooks R. PMID: 42428456 [PubMed - in process]
	Uterine fibroids reduce the sensitivity of ultrasound to detect endometrioid and serous endometrial cancer: a retrospective cohort study. Gynecol Pelvic Med Najor AJ, Aspir TB, Fife AJ, Tagoe UJ, Hussein NM, Moran ST, Grant KR, Isani SS, Cowan MW, Nevadunsky NS, Rotenberg OD, Lin KY. PMID: 42428452 [PubMed - in process]
	Cytopathological Findings of Axillary Lymph Nodes in Patients with Breast Cancer in Correlation with Ultrasound Findings. Iran J Pathol Almukhtar ZK, Kareem NM, Abduljabbar ST, Mohsein OA. PMID: 42428342 [PubMed - in process]
	The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basal-like and HER2-enriched breast cancer. medRxiv Bernard PS, Chen BE, Gao D, Shepherd LE, Nielsen TO, Varley KE. PMID: 42428078 [PubMed - in process]
	Method development and validation for determination of entinostat in human plasma and its application in breast cancer patients. RSC Adv Li S, Xu Y, Dong J, Qiu Y, Yang Z, Gao X, Gao J, Feng Z, Wang C, Wang M. PMID: 42427409 [PubMed - as supplied by publisher]
	An Integrated Statistical and Machine Learning Approach for Breast Cancer Classification Using Tumor Morphological Features. Biomed Res Int Woudneh AF, Shiferaw NT, Gebrie YF, Nigussie MM, Cherie KT, Gebeyehu FG. PMID: 42427209 [PubMed - in process]
	Intake of polyphenols, phenolic acids and lignans associated with lower mortality in women diagnosed with breast cancer. Br J Nutr Silva ER, Kliemann N, Vieira LC, de Souza JS, Copetti CL, Reitz LK, Vieira FK, Di Pietro PF. PMID: 42427097 [PubMed - as supplied by publisher]
	Large-scale transcriptome analysis reveals KIF20A as a novel indicator of cisplatin resistance in high-grade serous ovarian cancer. J Ovarian Res Cheng L, Wang X, Zhang J, Cai Q, Meng S, Li J, Yu P, Zhang Y, Wang S, Hao D, Li M, Li H. PMID: 42426841 [PubMed - as supplied by publisher]
	Illness perception of breast cancer among patients receiving treatment in a university teaching hospital, South-west Nigeria: a qualitative phenomenological study. BMC Cancer Esan DT, Onabanjo OD, Rasaq NO, Ramos CG. PMID: 42426653 [PubMed - as supplied by publisher]
	Repositioning osteocytes as integrative regulators of breast cancer bone metastasis. Oncogene Yi Y, Wang C, Yu X. PMID: 42426271 [PubMed - as supplied by publisher]
	Evolution of germline testing, mutation spectrum and clinico-pathological features in male breast cancer: a 27-year retrospective cohort including 69 patients. Cancer Genet Taris N, Amand NDS, Hild C, Mathelin C, Chrétien M. PMID: 42425871 [PubMed - as supplied by publisher]
	Targeting Lipid Metabolism Enzymes in Breast Cancer: Mechanistic Basis and Therapeutic Vulnerabilities. Eur J Pharmacol Li X, Hao H. PMID: 42425388 [PubMed - as supplied by publisher]
	Incidence and Predictors of Fat Necrosis After Single-Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer: Results From a Phase II Clinical Trial. Int J Radiat Oncol Biol Phys Facondo G, Prisco A, Reverberi C, Festa E, Moretti E, Bassi S, Marfisi D, Scalchi P, Trovò M. PMID: 42425251 [PubMed - as supplied by publisher]
	Pathophysiological affair between protein kinase D and epithelial ovarian cancer: A roadmap towards translating the mechanism from bench to bedside. Biochim Biophys Acta Rev Cancer Roy A. PMID: 42425229 [PubMed - as supplied by publisher]
	What is Optimal Neoadjuvant Therapy in HER2-Positive Breast Cancer? J Natl Compr Canc Netw Peiffer DS, Maloney C, Chen N. PMID: 42425154 [PubMed - in process]
	Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis. Int J Gynecol Cancer Corbaux P, You B, McNeish I, Welch S, Tinker AV, Mirza MR, Lindemann K, Kagimura T, Ray-Coquard IL, Subtil F, Péron J, Carty K, Kelly C, Colomban O, Karamouza E, Cook A, Paoletti X, Glasspool RM, Yanaihara N. PMID: 42425044 [PubMed - as supplied by publisher]
	Assessment of national cancer care network guideline-adherent treatment differences as a contributor to racial disparities in epithelial and non-epithelial ovarian cancer survival. Cancer Treat Res Commun Barragan M, David SM, Chen Z, Richardson K, Qiang W, Miodragovic D, Peterson CE. PMID: 42424989 [PubMed - as supplied by publisher]
	Exploring Breast Cancer Survivors' Preferences for Text Messaging-Based Mobile Health Interventions Targeting Sleep and Physical Activity: Qualitative Study. JMIR Form Res Tsai CS, Szewczyk W, Lee H, Drerup M, Blakeney EA, Greenlee H, Heffner JL, Vasbinder A, Reding KW. PMID: 42424632 [PubMed - in process]

Artikel 1 - 20 / 331893

Seite 1 von 16595

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung